Aayesha J. Soni , Yashvir Rugbeer , Julius Rozmiarek , Abi Manesh , Suzaan Marais
{"title":"肿瘤坏死因子-α拮抗剂在复杂性脊柱结核患者中的应用：病例系列和文献综述。","authors":"Aayesha J. Soni , Yashvir Rugbeer , Julius Rozmiarek , Abi Manesh , Suzaan Marais","doi":"10.1016/j.idnow.2024.104941","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Spinal tuberculosis is often associated with poor outcomes; host-directed inflammation involving the spine contributes to this disability.</p></div><div><h3>Methods</h3><p>A retrospective review of patients with complicated spinal tuberculosis having received tumor necrosis factor-alpha (TNF-α) antagonists at a referral hospital in South Africa. A literature review was performed to identify all published cases of complicated spinal tuberculosis that received a TNF-α antagonist as part of their treatment.</p></div><div><h3>Results</h3><p>We describe 23 cases, of which 19 were previously reported in the literature. All patients were treated with either thalidomide (n<!--> <!-->=<!--> <!-->6) or infliximab (n<!--> <!-->=<!--> <!-->16), except for one who received both. All in all, 21 (91%) cases improved neurologically and, at the end of follow-up, 18 could walk.</p></div><div><h3>Conclusion</h3><p>There is accumulating experience to confer the efficacy and safety of TNF-α antagonists in treating complicated spinal tuberculosis cases. Evidence from randomized controlled trials is urgently required to substantiate these findings.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104941"},"PeriodicalIF":2.9000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001088/pdfft?md5=1c1b2b3269708c2f4f5882c94dd65920&pid=1-s2.0-S2666991924001088-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Tumor necrosis factor-alpha antagonists in patients with complicated spinal tuberculosis: A case series and literature review\",\"authors\":\"Aayesha J. Soni , Yashvir Rugbeer , Julius Rozmiarek , Abi Manesh , Suzaan Marais\",\"doi\":\"10.1016/j.idnow.2024.104941\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Spinal tuberculosis is often associated with poor outcomes; host-directed inflammation involving the spine contributes to this disability.</p></div><div><h3>Methods</h3><p>A retrospective review of patients with complicated spinal tuberculosis having received tumor necrosis factor-alpha (TNF-α) antagonists at a referral hospital in South Africa. A literature review was performed to identify all published cases of complicated spinal tuberculosis that received a TNF-α antagonist as part of their treatment.</p></div><div><h3>Results</h3><p>We describe 23 cases, of which 19 were previously reported in the literature. All patients were treated with either thalidomide (n<!--> <!-->=<!--> <!-->6) or infliximab (n<!--> <!-->=<!--> <!-->16), except for one who received both. All in all, 21 (91%) cases improved neurologically and, at the end of follow-up, 18 could walk.</p></div><div><h3>Conclusion</h3><p>There is accumulating experience to confer the efficacy and safety of TNF-α antagonists in treating complicated spinal tuberculosis cases. Evidence from randomized controlled trials is urgently required to substantiate these findings.</p></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"54 6\",\"pages\":\"Article 104941\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666991924001088/pdfft?md5=1c1b2b3269708c2f4f5882c94dd65920&pid=1-s2.0-S2666991924001088-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991924001088\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991924001088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Tumor necrosis factor-alpha antagonists in patients with complicated spinal tuberculosis: A case series and literature review
Introduction
Spinal tuberculosis is often associated with poor outcomes; host-directed inflammation involving the spine contributes to this disability.
Methods
A retrospective review of patients with complicated spinal tuberculosis having received tumor necrosis factor-alpha (TNF-α) antagonists at a referral hospital in South Africa. A literature review was performed to identify all published cases of complicated spinal tuberculosis that received a TNF-α antagonist as part of their treatment.
Results
We describe 23 cases, of which 19 were previously reported in the literature. All patients were treated with either thalidomide (n = 6) or infliximab (n = 16), except for one who received both. All in all, 21 (91%) cases improved neurologically and, at the end of follow-up, 18 could walk.
Conclusion
There is accumulating experience to confer the efficacy and safety of TNF-α antagonists in treating complicated spinal tuberculosis cases. Evidence from randomized controlled trials is urgently required to substantiate these findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
